JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Bio-Techne Corp

Chiusa

SettoreSettore sanitario

54.68 -0.33

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

53.84

Massimo

55.17

Metriche Chiave

By Trading Economics

Entrata

-12M

23M

Vendite

19M

316M

P/E

Media del settore

66.121

40.048

Rendimento da dividendi

0.58

Margine di Profitto

7.144

Dipendenti

3,100

EBITDA

-7.1M

68M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+19.33% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.58%

2.45%

Utili prossimi

6 ago 2025

Prossima data del Dividendo

29 ago 2025

Prossima data del' Ex Dividendo

18 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.9B

8.6B

Apertura precedente

55.01

Chiusura precedente

54.68

Notizie sul Sentiment di mercato

By Acuity

52%

48%

309 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Bio-Techne Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 ago 2025, 23:11 UTC

Utili

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 ago 2025, 22:45 UTC

Utili

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 ago 2025, 22:39 UTC

Utili

Great-West Lifeco Logs Lower 2Q Profit

5 ago 2025, 21:32 UTC

Utili

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 ago 2025, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 ago 2025, 23:40 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 ago 2025, 23:19 UTC

Discorsi di Mercato

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 ago 2025, 23:03 UTC

Discorsi di Mercato
Utili

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 ago 2025, 22:22 UTC

Utili

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 ago 2025, 22:21 UTC

Utili

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 ago 2025, 22:20 UTC

Utili

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 ago 2025, 22:18 UTC

Utili

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 ago 2025, 22:17 UTC

Utili

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 ago 2025, 22:17 UTC

Utili

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 ago 2025, 22:16 UTC

Utili

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 ago 2025, 22:16 UTC

Utili

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 ago 2025, 22:15 UTC

Utili

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 ago 2025, 22:13 UTC

Utili

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 ago 2025, 22:13 UTC

Utili

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 ago 2025, 22:12 UTC

Utili

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 ago 2025, 22:12 UTC

Utili

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 ago 2025, 21:58 UTC

Utili

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 ago 2025, 21:30 UTC

Utili

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 ago 2025, 21:26 UTC

Utili

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 ago 2025, 21:23 UTC

Utili

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 ago 2025, 21:17 UTC

Utili

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Confronto tra pari

Modifica del prezzo

Bio-Techne Corp Previsione

Obiettivo di Prezzo

By TipRanks

19.33% in crescita

Previsioni per 12 mesi

Media 65.5 USD  19.33%

Alto 75 USD

Basso 58 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Bio-Techne Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

9

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

49.67 / 50.24Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

309 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.